{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenovirus&page=2",
    "query": {
      "condition": "Adenovirus",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenovirus&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:08:24.133Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02830932",
      "title": "Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus (RSV)"
      ],
      "interventions": [
        {
          "name": "VXA-RSV-f Tablets (high dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VXA Placebo Tablets",
          "type": "OTHER"
        },
        {
          "name": "VXA-RSV-f Tablets (low dose)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Vaxart",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 66,
      "start_date": "2016-06-22",
      "completion_date": "2017-09-20",
      "has_results": false,
      "last_update_posted_date": "2018-08-16",
      "last_synced_at": "2026-05-22T03:08:24.133Z",
      "location_count": 1,
      "location_summary": "Melbourne, Florida",
      "locations": [
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02830932"
    },
    {
      "nct_id": "NCT00384787",
      "title": "Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VRC-HIVDNA009-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-HIVADV014-00-VP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 90,
      "start_date": "2006-11",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-05-22T03:08:24.133Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00384787"
    },
    {
      "nct_id": "NCT00301106",
      "title": "Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "adenovirus-mediated human interleukin-12",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Max Sung",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 85 Years · Female only"
      },
      "enrollment_count": 2,
      "start_date": "2005-10",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2017-02-02",
      "last_synced_at": "2026-05-22T03:08:24.133Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00301106"
    },
    {
      "nct_id": "NCT06605378",
      "title": "Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Granulomatous Disease (CGD)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ensoma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 60,
      "start_date": "2024-11-18",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-05-22T03:08:24.133Z",
      "location_count": 50,
      "location_summary": "Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06605378"
    },
    {
      "nct_id": "NCT07444606",
      "title": "Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "DNX-2401",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2026-08-31",
      "completion_date": "2029-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-05-22T03:08:24.133Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07444606"
    },
    {
      "nct_id": "NCT00880464",
      "title": "Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Autologous, Lethally Irradiated Breast Cancer Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2006-01-01",
      "completion_date": "2021-06",
      "has_results": true,
      "last_update_posted_date": "2022-04-01",
      "last_synced_at": "2026-05-22T03:08:24.133Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00880464"
    },
    {
      "nct_id": "NCT01431326",
      "title": "Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adenovirus",
        "Anesthesia",
        "Anxiety",
        "Anxiolysis",
        "Autism",
        "Autistic Disorder",
        "Bacterial Meningitis",
        "Bacterial Septicemia",
        "Benzodiazepine",
        "Bipolar Disorder",
        "Bone and Joint Infections",
        "Central Nervous System Infections",
        "Convulsions",
        "Cytomegalovirus Retinitis",
        "Early-onset Schizophrenia Spectrum Disorders",
        "Epilepsy",
        "General Anesthesia",
        "Gynecologic Infections",
        "Herpes Simplex Virus",
        "Infantile Hemangioma",
        "Infection",
        "Inflammation",
        "Inflammatory Conditions",
        "Intra-abdominal Infections",
        "Lower Respiratory Tract Infections",
        "Migraines",
        "Pain",
        "Pneumonia",
        "Schizophrenia",
        "Sedation",
        "Seizures",
        "Skeletal Muscle Spasms",
        "Skin and Skin-structure Infections",
        "Treatment-resistant Schizophrenia",
        "Urinary Tract Infections",
        "Withdrawal",
        "Sepsis",
        "Gram-negative Infection",
        "Bradycardia",
        "Cardiac Arrest",
        "Cardiac Arrhythmia",
        "Staphylococcal Infections",
        "Nosocomial Pneumonia",
        "Neuromuscular Blockade",
        "Methicillin Resistant Staphylococcus Aureus",
        "Endocarditis",
        "Neutropenia",
        "Headache",
        "Fibrinolytic Bleeding",
        "Pulmonary Arterial Hypertension",
        "CMV Retinitis",
        "Hypertension",
        "Chronic Kidney Diseases",
        "Hyperaldosteronism",
        "Hypokalemia",
        "Heart Failure",
        "Hemophilia",
        "Heavy Menstrual Bleeding",
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel Benjamin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 3520,
      "start_date": "2011-11",
      "completion_date": "2019-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-06",
      "last_synced_at": "2026-05-22T03:08:24.133Z",
      "location_count": 43,
      "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431326"
    },
    {
      "nct_id": "NCT02685020",
      "title": "Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ad26.Mos.HIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Clade C gp140",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2016-03-28",
      "completion_date": "2019-01-03",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-05-22T03:08:24.133Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02685020"
    },
    {
      "nct_id": "NCT03125473",
      "title": "Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Norovirus Gastroenteritis"
      ],
      "interventions": [
        {
          "name": "VXA-G1.1-NN Oral Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vaxart",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "19 Years to 49 Years"
      },
      "enrollment_count": 66,
      "start_date": "2017-04-07",
      "completion_date": "2018-05-06",
      "has_results": false,
      "last_update_posted_date": "2018-05-30",
      "last_synced_at": "2026-05-22T03:08:24.133Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03125473"
    },
    {
      "nct_id": "NCT00849459",
      "title": "Gene Therapy in Treating Women With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "adenovirus-mediated human interleukin-12",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Max Sung",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 3,
      "start_date": "2008-08",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-05-22T03:08:24.133Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00849459"
    }
  ]
}